It is hard to find anything but good news in the current weekly insider-sentiment data from Vickers Stock Research. Volatility remains the order of the day in the stock market -- but for three consecutive weeks, the data from Vickers has suggested a bottom may be near, or already in. Let's jump right to the numbers. Vickers' NYSE One-Week Sell/Buy Ratio is 1.30 this week, this on a scale where anything below 2.00 is bullish. The ratio has been bullish for the past three weeks. Moving to the Nasdaq, the one-week ratio is 2.40. That is still neutral but closing in on bullish, and the ratio has been strong enough of late to engender nine consecutive weeks of improvement in the broader Nasdaq Eight-Week Sell/Buy Ratio. That reading has improved to 3.28 (neutral) from 5.20 back on March 10. All of the above has Vickers' Total (all exchanges) One-Week Sell/Buy Ratio at a bullish 1.76 and the Total Eight-Week Sell/Buy Ratio close to bullish at 2.63 after nine weeks of improvement. On a sector basis, insider buying exceeded selling in Financials last week, with shares valued at $4.5 million bought versus $3.9 million sold. Buying also outpaced selling in Energy, although volume was light with less than $100,000 shares bought during the period. Selling was the greatest in Consumer Discretionary over the last week, with shares valued at $21 million sold versus just $2 million bought. Selling was also notable in Industrials, Consumer Staples, and Healthcare. This week, analysts at Vickers highlighted insider transactions of interest at HEICO Corp. (NYSE: HEI) and Elevance Health Inc. (NYSE: ELV).

GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 44,000 commercial and 26,000 military aircraft engines. Based in Ohio, the company has 52,000 employees. GE shares are a component of the S&P 500.

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

In this edition, Daikin looks like a cool deal; Roblox has some building to do; Domino's pizza hasn't gotten cold quite yet; and PepsiCo, Regeneron, and BCE.